<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980210</url>
  </required_header>
  <id_info>
    <org_study_id>2018_63</org_study_id>
    <secondary_id>2019-A00053-54</secondary_id>
    <nct_id>NCT03980210</nct_id>
  </id_info>
  <brief_title>Effect of Hyperbaric Oxygen Therapy on Microcirculation</brief_title>
  <acronym>MICROHB</acronym>
  <official_title>Effect of Hyperbaric Oxygen Therapy on Healthy Volunteers Microcirculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies shoes that hyperoxia alters microcirculation.The investigators hypothesize
      that hyperbaric may restore microcirculation integrity. This hypothesis is supported by a
      recent study in rabbits, but no data exists for humans.

      The study will expose fifteen healthy volunteers to a succession of different fraction of
      inspired oxygen and barometric pressure and assess microcirculatory and macrocirculatory
      changes via sidestream dark field videomicroscopy, near-infrared spectroscopy, Laser Doppler,
      transthoracic echocardiography and bio-impedancemetry at every step.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microcirculation alterations and hyperoxia are known to alter ICU-patients' prognostic.

      Studies have shown that hyperoxia alters healthy volunteers' microcirculation, whereas
      hyperbaric oxygen therapy is commonly used to facilitate cicatrization. There seems to be a
      paradox. A recent study in rabbits has given some evidences that hyperbaria may restore
      microcirculation integrity, but to date, there is no such evidences in human.

      To study hyperoxia and hyperbaric induced changes in micro and macrocirculation, fifteen
      healthy volunteers will be exposed to successive variations of inspired oxygen fraction and
      barometric pressure according to a predefine sequence so that only one parameter will change
      from a condition to the next one :

        1. FiO2 0.21 - 1 ATA

        2. FiO2 1 - 1 ATA

        3. FiO2 1 - 2.5 ATA

        4. FiO2 0.21 - 2.5 ATA

        5. FiO2 0.21 - 1 ATA

      At each time, and after a 30 minutes period of exposure, measures will be made using
      SDF-microscopy, Laser Doppler and NIRS to assess microcirculation.

      As previously described, macrocirculation can modify microcirculation due to a mechanism
      called hemodynamic coherence.

      Hence, the investigators planned to assess macrocirculation changes at every step of the
      protocol using bioimpedancemetry and transthoracic echocardiography.

      Each volunteer will be his own control, using the first measurements (condition 1. FiO2 0.21
      - 1 ATA) as reference.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Actual">July 25, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after hyperbaric hyperoxia exposure (FiO2 1 - 2.5 ATA)</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after FiO2 1 - 1 ATA exposure</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in proportion of perfused vessel (PPV)</measure>
    <time_frame>30 minutes after FiO2 0.21 - 2.5 ATA exposure</time_frame>
    <description>Proportion of perfused vessel assessed by Sidestream dark field microscopy on the sublingual mucosa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hyperemic reaction after a vaso-occlusion test</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Area under curve assessed by near-infrared spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in area of hyperaemia after a vaso-occlusion test</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Area under curve assessed by Laser-Doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Validation of cardiac output assessed by bioimpedancemetry under hyperbaric condition</measure>
    <time_frame>30 minutes after FiO2 1 - 2.5 ATA exposure</time_frame>
    <description>Comparison with transthoracic echocardiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hyperbaric Oxygen Therapy</condition>
  <arm_group>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Successive changes in fraction of inspired oxygen and barometric pressure (ATA: Atmosphere absolute)
Five successive steps:
FiO2 0.21 - 1 ATA
FiO2 1 - 1 ATA
FiO2 1 - 2.5 ATA
FiO2 0.21 - 2.5 ATA
FiO2 0.21 - 1 ATA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperbaric oxygen therapy</intervention_name>
    <description>FiO2 0.21 - 1 ATA
FiO2 1 - 1 ATA
FiO2 1 - 2.5 ATA
FiO2 0.21 - 2.5 ATA
FiO2 0.21 - 1 ATA</description>
    <arm_group_label>Hyperbaric oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To provide a medical certificate of fitness to dive (&lt; 1 year)

          -  Consent given for study participation

          -  French health insurance affiliated

        Exclusion Criteria:

          -  Temporary or definitive contra-indication to dive

          -  Pregnancy or &lt; 18 years of age

          -  Precedent dive &lt; 24 hours

          -  Under a legal protection measure

          -  Medical history of a disease known to alter microcirculation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibault Duburcq, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperbaric oxygen therapy</keyword>
  <keyword>Normobaric oxygen therapy</keyword>
  <keyword>Hyperoxia</keyword>
  <keyword>Sidestream dark field videomicroscopy</keyword>
  <keyword>Microcirculation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

